Dexgate
CVE-2023-42435
HIGH
Severity by source
AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H
Primary rating from NVD · only source for this CVE.
CVSS VectorNVD
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H
Lifecycle Timeline
1DescriptionNVD
The affected product is vulnerable to a cross-site request forgery vulnerability, which may allow an attacker to perform actions with the permissions of a victim user.
AnalysisAI
The affected product is vulnerable to a cross-site request forgery vulnerability, which may allow an attacker to perform actions with the permissions of a victim user. Rated high severity (CVSS 8.8), this vulnerability is remotely exploitable, no authentication required, low attack complexity. No vendor patch available.
Technical ContextAI
This vulnerability is classified as Cross-Site Request Forgery (CSRF) (CWE-352), which allows attackers to trick authenticated users into performing unintended actions. The affected product is vulnerable to a cross-site request forgery vulnerability, which may allow an attacker to perform actions with the permissions of a victim user. Affected products include: Dexma Dexgate.
RemediationAI
No vendor patch is available at time of analysis. Monitor vendor advisories for updates. Implement anti-CSRF tokens, validate Origin/Referer headers, use SameSite cookie attribute.
The affected product is vulnerable to an improper authentication vulnerability, which may allow an attacker to impersona
The affected product is vulnerable to a cleartext transmission of sensitive information vulnerability, which may allow a
The affected product is vulnerable to a cross-site scripting vulnerability, which could allow an attacker to access the
The affected product is vulnerable to an exposure of sensitive information to an unauthorized actor vulnerability, which
Same weakness CWE-352 – Cross-Site Request Forgery (CSRF)
View allShare
External POC / Exploit Code
Leaving vuln.today